@article{6f53f2d1e41a4aebb7b854d6d8281124,
title = "Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)",
abstract = "Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper. The original article has been corrected.",
author = "Nowakowski, {Grzegorz S.} and Yoon, {Dok Hyun} and Patrizia Mondello and Erel Joffe and Anthea Peters and Isabelle Fleury and Richard Greil and Matthew Ku and Reinhard Marks and Kibum Kim and Zinzani, {Pier Luigi} and Judith Trotman and Lorenzo Sabatelli and Waltl, {Eva E.} and Mark Winderlich and Andrea Sporchia and Kurukulasuriya, {Nuwan C.} and Raul Cordoba and Georg Hess and Gilles Salles",
note = "Publisher Copyright: {\textcopyright} 2023, Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2023",
month = sep,
doi = "10.1007/s00277-023-05321-3",
language = "English (US)",
volume = "102",
pages = "2643--2644",
journal = "Annals of hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",
}